Long perceived as gadgets, digital therapies are reaching a milestone. With “Joe†, a fun device intended for children, the High Health Authority recognizes a concrete clinical benefit. A development which also tells, implicitly, the silent challenges of pediatric asthma.
When technology invites itself into the intimacy of care
This is a first that could be a landmark. On April 2, 2026, the High Health Authority issued a favorable opinion on the reimbursement of digital therapy, a decision that was still unimaginable a few years ago.
At the heart of this progress: “Joe†, a device designed to support asthmatic children in their daily treatment. Concretely, it is a small robot with a screen, associated with an application configured by parents. through videos educational and reminders, it guides the child in his care actions.
Behind this object, an often invisible reality: that of families confronted with a demanding chronic illness. In France, asthma affects between 14 and 16% of children. And beyond the crises, constant vigilance is required: taking treatment, preventing exacerbations, coordinating with caregivers. In this context, therapeutic education is not a simple complement. It is at the heart of care, but it relies largely on the involvement of parents, sometimes exhausted, and on the child’s ability to master complex gestures.
Pr Céline Delestrain, pneumo-pediatrician, Center Hospitalier Intercommunal de Créteil, explains: “In consultation, we see children whose asthma remains insufficiently controlled, despite effective treatments. Behind this, there are often recurring difficulties: imperfect inhalation technique, irregular doses, children whose quality of life is deteriorating and destitute parents. These situations generate tension and a feeling of failure for both families and caregivers. We explain in consultation, but everything is played out at home”.
This is precisely where digital therapies are trying to fit in: not to replace care, but to make it more accessible, more concrete, more alive.
Expected results… and finally there
If the decision of the High Health Authority marks a turning point, it is not the result of spontaneous enthusiasm. Quite the contrary. In 2025, a first assessment was revealed to be unfavorable. The reason: a lack of solid data to demonstrate the real effectiveness of the system. A caution which illustrates the rigor of the evaluation process.
But in the meantime, new data has been produced. And they changed the situation. According to the analysis of the National Commission for the Evaluation of Medical Devices, digital therapy “Joe†, when combined with standard treatment, turns out to be superior to standard treatment alone in children aged 7 to 11 years.
The most significant benefit concerns the reduction in exacerbations – these sometimes violent attacks which can lead to hospitalization. In a randomized controlled clinical study carried out nationally, JOE Digital Therapy demonstrated a reduction of 42 % of severe exacerbations in children aged 7 to 11 with persistent asthma (GINA grades 4 and 5) An improvement which, for families, means less anxiety, fewer trips to the emergency room, and a slightly calmer daily life.
On the other hand, this effectiveness has not been demonstrated in younger people, between 4 and 7 years old. An important limitation, which reminds us that these tools are not universal and still need to be refined.
The HAS thus recognizes a “sufficient expected service” and a “minor improvement in the expected service (level IV)”. A technical formulation, but full of meaning: the system brings a real benefit, even if it remains modest.
A discreet revolution, still under surveillance
Beyond the case of “Joe†, this decision opens a gap in the healthcare landscape. Digital therapies – or DTx – are developing rapidly. Applications for depression, programs for insomnia, support tools for chronic illnesses… Their promise is attractive: personalize care, extend support outside the hospital, give the patient an active role again.
Alexandra de la Fontaine, CEO of LUDOCARE, declares: “This decision marks a major step for DTx in France, for Ludocare, but also for patients and their families. It opens the way to a new generation of therapeutic class. This is a positive message sent to innovative companies that invest, for the benefit of patients, healthcare professionals and the healthcare system.”.
But this promise comes with strong demands. The HAS clearly points out: the company will have to carry out a study in real conditions over 12 months. Objective: measure long-term effectiveness, particularly on the number of exacerbations, compliance with treatment and the possibility of reducing certain medications. In other words, vigilance remains essential. Because behind the innovation, a question remains: can these tools sustainably transform care, or are they only one-off support?
For the families concerned, the answer is played out on a daily basis. In these ordinary moments – a treatment reminder, a well-performed gesture, a crisis averted – which, taken end to end, profoundly change life. This first official recognition does not signify a spectacular revolution. Rather, it depicts a gradual, almost silent, evolution of care. A medicine which, little by little, invites itself into the living room, into the child’s bedroom, into daily routines.
And which, perhaps, finally allows us to breathe a little.
